Devah Therapeutics repurposes clinically proven molecules using the FDA 505(b)(2) pathway to develop faster, lower‑risk treatments for stress‑related, metabolic and CNS disorders such as PTSD, perimenopausal vasomotor symptoms, and hyperuricemia. By applying modern mechanistic studies to a legacy chemistry estate, the company shortens preclinical and early clinical timelines and offers pharmaceutical partners new therapeutic options for high‑unmet‑need indications.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with stress‑related, metabolic, and central nervous system disorders often lack effective treatments because drug development is lengthy, costly, and carries high clinical risk, especially for conditions with unmet needs such as PTSD, perimenopausal vasomotor symptoms, and hyperuricemia.
Solution
Devah Therapeutics addresses this gap by repurposing molecules that have already demonstrated safety and pharmacology in humans. Leveraging the FDA 505(b)(2) regulatory pathway, the company accelerates development timelines while reducing clinical and financial risk. Modern scientific tools are applied to re‑evaluate these legacy compounds for new mechanisms, targeting dysregulated stress‑axis biology, thermoregulatory pathways, and metabolic regulation. The approach aims to restore physiological balance and improve quality of life for patients whose conditions are currently underserved.
Target Audience
Primary customers are pharmaceutical partners and healthcare providers seeking new, evidence‑based treatments for stress‑related, metabolic, and CNS disorders with high unmet clinical need.
Features
- Utilization of a 40‑year‑old chemistry estate with established safety data to shorten preclinical and early clinical phases
- Application of contemporary mechanistic studies (e.g., PDE inhibition, HPA‑axis modulation) to identify novel therapeutic indications
- Focus on three primary targets: PTSD & anxiety disorders, perimenopausal vasomotor symptoms, and hyperuricemia/gout
- Strategic use of the FDA 505(b)(2) pathway to streamline regulatory approval and lower development costs
- Integrated translational program that aligns molecular pharmacology with stress‑related and metabolic disease pathways